It is also the first report to include hereditary prostate cancer patients, which enabled us to test whether the degree of association between the polymorphisms of CYP1B1 and prostate cancer risk is strong enough to contribute to familial aggregation of prostate cancer. This evidence concerns the gene CYP1B1 and prostate cancer.